The evolution of integrated treatment of soft tissue sarcoma at the Rizzoli Orthopaedic Institute.

F. Gherlinzoni, P. Picci, M. Mercuri, G. Bacci, S. Frustaci, A. De Paoli, E. Barbieri

Research output: Contribution to journalArticlepeer-review

Abstract

The authors take into consideration all types of treatment used at the Rizzoli Orthopaedic Institute and in associated centers over the last 40 years for soft tissue sarcoma of the limbs. For each clinical study the most up-to-date results are reported with statistical evaluations. From the first protocol that used adriamycin alone and up to the beginning of the eighties, we then go on to a second-generation study in the nineties that used adriamycin and ifosphamide at a high dosage. The pilot study that was used at the end of the nineties to evaluate the validity of the use of chemotherapy and radiotherapy is considered, as is the study currently being conducted by the Italian Sarcoma Group. Conclusions based on our vast previous experience lead us to believe that adjuvant chemotherapy must be used for all patients with high-risk soft tissue sarcoma within clinical trials.

Original languageEnglish
Pages (from-to)95-105
Number of pages11
JournalLa Chirurgia degli organi di movimento
Volume89
Issue number2
Publication statusPublished - 2004

Fingerprint

Dive into the research topics of 'The evolution of integrated treatment of soft tissue sarcoma at the Rizzoli Orthopaedic Institute.'. Together they form a unique fingerprint.

Cite this